Largest US pharmaceutical distributor, delivering drugs and medical-surgical supplies to pharmacies, hospitals and providers, plus oncology platforms.
Largest US pharmaceutical distributor, delivering drugs and medical-surgical supplies to pharmacies, hospitals and providers, plus oncology platforms.
Buys drugs from manufacturers and sells them to pharmacies and hospitals at a small markup on huge volume, with generic-drug contracts helping the margin. It also runs oncology practices through the US Oncology Network and sells medical-surgical supplies. It is one of three big US drug wholesalers, with Cencora and Cardinal.
Moat: narrow (scale, distribution, switching costs). Massive logistics scale and entrenched distribution contracts across the US drug supply chain.
Headquarters: Irving, Texas, USA · Founded: 1833 · Employees: 43,000
Size McKesson (MCK) is a United States Health Care company (Medical Distributors) with a market value of $125B, the 97th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1,084 on 18 Nov 2026.
Performance Over six months the shares gained 43.7%, against +11.7% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +6.2%); the operating margin is 1.7% (peer median 2.9%).
Valuation It trades at 22.1× forward earnings against a peer median of 17.0× (4th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 80.3 points above its cost of capital (6.5% WACC).
Credit McKesson has 10 bonds outstanding ($4.89B), rated BBB+ by the agencies and trading like A at a weighted spread of 64 bp.
Short interest Short interest is 1.7% of the free float (30 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $419B | $403B | $359B | $309B | $277B |
| Revenue growth | — | +12% | +16% | +12% | — |
| Gross profit | $14.6B | $14.1B | $12.5B | $12.2B | $11.9B |
| EBITDA | $7.87B | $6.68B | $5.01B | $4.56B | $5.31B |
| Net income | $4.70B | $4.76B | $3.29B | $3.00B | $3.56B |
| Free cash flow | $7.11B | $5.72B | $5.55B | $3.88B | $4.77B |
| Capital expenditure | $635M | $745M | $859M | $687M | $558M |
| Total debt | $11.2B | $8.61B | $7.39B | $7.39B | $7.29B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| McKesson MCK | $125B | +44% | +8% | 2% | 22.1× | -5.5% |
| Cencora COR | $66.5B | +32% | +5% | 1% | 17.7× | -1.2% |
| Cardinal Health CAH | $64.3B | +40% | +10% | 1% | 21.1× | 7.8% |
| CVS Health CVS | $104B | -13% | +7% | 4% | 9.6× | -3.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MCK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.3% | +1.8% | 6th highest of 21 |
| 6-month return | +43.7% | +11.7% | 4th highest of 21 |
| Distance from 52-week high | -3.3% | -13.2% | 3rd highest of 21 |
| Revenue growth (TTM) | +8.2% | +6.2% | 8th highest of 21 |
| Operating margin | 1.7% | 2.9% | 9th lowest of 21 |
| Forward P/E | 22.1× | 17.0× | 4th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -5.5% | -1.2% | 7th least demanding of 18 |
| Growth delivered (Del g) | +11.1% | +5.4% | 2nd highest of 18 |
| Hurdle (Req g minus delivered) | -16.6 pp | -8.0 pp | 2nd least demanding of 18 |
| ROIC minus cost of capital | +80.3 pp | +1.6 pp | highest of 20 |
| Net debt / EBITDA | 0.6× | 0.8× | 8th least indebted of 18 |
| Bond spread | 64 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| McKesson MCK | United States | $125B | +44% | +8% | 2% | 22.1× | -5.5% | +11.1% |
| Cencora COR | United States | $66.5B | +32% | +5% | 1% | 17.7× | -1.2% | +9.5% |
| Cardinal Health CAH | United States | $64.3B | +40% | +10% | 1% | 21.1× | 7.8% | +9.4% |
| Henry Schein HSIC | United States | $9.47B | +17% | +6% | 6% | 14.7× | 10.2% | +5.4% |
| Sinopharm 1099.HK | Hong Kong | $6.74B | 0% | +3% | 3% | 6.2× | -7.3% | +4.0% |
| DKSH DKSH.SW | Switzerland | $5.99B | +24% | -1% | 3% | 21.8× | -1.2% | +0.6% |
| Galenica GALE.SW | Switzerland | $5.31B | +8% | +6% | 5% | 23.9× | 7.0% | +3.5% |
| Jointown Pharmaceutical 600998.SS | China | $3.99B | +7% | +9% | 2% | 11.8× | 0.2% | +7.8% |
| MEDIPAL 7459.T | Japan | $3.70B | +15% | +4% | 1% | 12.5× | -7.2% | +3.5% |
| Amplifon AMP.MI | Italy | $3.39B | +8% | 0% | 10% | 17.0× | 6.8% | +9.8% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 15.9× | n/a | n/a |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 18.4× | -8.4% | +3.5% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% | +12.7% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | n/a | 26.0% | +9.6% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
McKesson has 10 bonds outstanding with $4.89B face value. The agencies rate it BBB+; its bonds trade like A. Weighted yield 5.36%, a spread of 64 bp over government bonds.